Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMZC9XU)

Drug Name
GSK-1360707 Drug Info
Synonyms Monoamine reuptake inhibitors (depression), GlaxoSmithKline; Serotonin/dopamine/norepinephrine reuptake inhibitors (depression), GlaxoSmithKline
Indication
Disease Entry ICD 11 Status REF
Major depressive disorder 6A70.3 Phase 1 [1]
Cross-matching ID
PubChem CID
24802841
CAS Number
CAS 1013098-04-8
TTD Drug ID
DMZC9XU

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine transporter (DAT) TTVBI8W SC6A3_HUMAN Inhibitor [2]
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [2]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Dopamine transporter (DAT) DTT SLC6A3 4 2.609 5.233 3.7
Norepinephrine transporter (NET) DTT SLC6A2 2.459 3.426 3.322 3.35
Serotonin transporter (SERT) DTT SLC6A4 6.278 5.469 6.075 6.966
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Major depressive disorder
ICD Disease Classification 6A70.3
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine transporter (DAT) DTT SLC6A3 1.08E-03 -3.08 -1.99
Serotonin transporter (SERT) DTT SLC6A4 8.76E-01 7.18E-05 6.19E-04
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01153802) An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Dosesof GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands. U.S. National Institutes of Health.
2 Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7.